Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe E. who wrote (3233)	12/8/1997 6:18:00 PM
From: Bhag Karamchandani	Read Replies (1) of 6136

I agree that the AGPH CEO missed a great opportunity to respond to Joe's lead in question about discontinuing the THYMITAQ trials being a potential positive, in terms of expense savings. The question I have : Why did Roche walk away, if the other drugs in the pipeline , with potentially large markets ( unfortunately) and relatively short horizons ( two to four years) are as promising as Johnson (today) and others have previously suggested on this thread. Roche has a reputation for good business sense - although their experience is mainly with blockbuster drugs. I hope THYMATIQ is available to those with terminal cancer of th liver, as a humanitarian gesture.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next